Advertisement

Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px
Organisation › Details

Spexis AG (SIX: ???)

Polyphor is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead product, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which has achieved clinical proof of concept in a Phase Ib/proof of concept study in combination with eribulin in patients with advanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near Basel and is listed on the Swiss Stock Exchange (SIX: POLN). *

 

Period Start 2000-10-29 planned merger
  Group Spexis (Group)
  Predecessor Polyphor Ltd. (SIX: POLN)
Products Industry antibiotic
  Industry 2 murepavadin (POL7080)
Persons Person Batur, Gökhan (Polyphor 202001– promoted to CEO joined 201906 as CCO before Merck (US))
  Person 2 Levett, Hernán (Polyphor 202001 CFO)
     
Region Region Allschwil BL
  Country Switzerland
  City n. a. 
    Address record changed: 2021-11-06
     
Basic data Employees C: 51 to 100 (2013-11-04)
  Currency CHF
  Annual sales 6,545,595 (revenue, total, consolidated (2018) 2018-12-31)
  Profit -50,920,282 (2018-12-31)
  Cash 113,809,266 (2018-12-31)
     
    * Document for �About Section�: Polyphor Ltd.. (7/17/18). "Press Release: Polyphor Announces Listing of New Shares Related to the Convertible Loan Facility Agreement with the Wellcome Trust (Ad-hoc Announcement)".
     
   
Record changed: 2021-11-06

Advertisement

Picture [iito] No Tracking 650x100px

More documents for Spexis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top